Tag: Novamind - Psilocybin Alpha

Visit our Psychedelic Legalization & Decriminalization Tracker

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

Post published:March 18, 2021
Post category:Press Release

Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter

Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter

Post published:March 1, 2021
Post category:Press Release

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Post published:February 22, 2021
Post category:Press Release

Novamind Announces Marketing Services Agreements

Novamind Announces Marketing Services Agreements

Post published:January 26, 2021
Post category:Press Release

Novamind Expands Psychedelic Medicine Access in Utah

Novamind Expands Psychedelic Medicine Access in Utah

Post published:January 13, 2021
Post category:Press Release

Novamind Completes Reverse Takeover Transaction

Novamind Completes Reverse Takeover Transaction

Post published:December 24, 2020
Post category:Press Release

Novamind Receives CSE Conditional Listing Approval Under the Ticker “NM”

Novamind Receives CSE Conditional Listing Approval Under the Ticker “NM”

Post published:December 22, 2020
Post category:Press Release

Novamind Closes Oversubscribed CAD$10 Million Private Placement

Novamind Closes Oversubscribed CAD$10 Million Private Placement

Post published:November 23, 2020
Post category:Press Release

Novamind and Hinterland Metals Enter into Amalgamation Agreement

Novamind and Hinterland Metals Enter into Amalgamation Agreement

Post published:November 17, 2020
Post category:Press Release

Novamind Sponsors TheraPsil, an Advocate for the Compassionate Use of Psilocybin in Canada

Novamind Sponsors TheraPsil, an Advocate for the Compassionate Use of Psilocybin in Canada

Post published:July 31, 2020
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.